Answers are grounded in this paper and cite their sources.
To characterize long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD).
No takes yet. Share an insight, caveat, or question.
Cree et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: